LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
Pre-Launchlamivudine; tenofovir disoproxil fumarate; nevirapine
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing lamivudine, tenofovir disoproxil fumarate, and nevirapine—three nucleoside/nucleotide reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor used to treat HIV-1 infection. The combination works by inhibiting viral reverse transcriptase, reducing viral replication and CD4+ T-cell decline. This oral tablet formulation simplifies dosing for HIV-positive patients.
PRE_LAUNCH
As a pre-launch product, this represents an early-stage opportunity with likely small initial commercial teams; expansion will depend on regulatory approval timing and competitive positioning in the HIV market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch HIV combination offers entry or growth opportunities in global health and infectious disease, with particular strength in emerging markets and access-focused roles. Career progression will accelerate if regulatory approval is granted and the product achieves commercial traction; otherwise, roles may transition to other portfolio assets post-launch delay.
Brand Manager
Worked on LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE at Matrix Surgical USA? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.